Personal HistoryEducation and Training
1997-1998: The University of Maryland Graduate School; M.A. in Applied and Professional Ethics: Bioethics and the Ethics of Healthcare Track.
1998-2002: The Medical College of Virginia of Virginia Commonwealth University; M.D. degree.
2002-2007: The University of Maryland / Sheppard Pratt Research & Clinical Residency in Psychiatry.
2007-2009: NIMH-Funded (T32) Schizophrenia Research Fellowship at the Maryland Psychiatric Research Center (MPRC), University of Maryland School of Medicine.
2007: Certified as Diplomat, American Board of Psychiatry and Neurology (ABPN); Number 57114.
Research InterestsDr. Fischer's research interests center around co-occurring mental illness and substance abuse disorders. He has a specific interest in psychopharmacology and the development of biomarkers for illness/treatment response. The populations Dr. Fischer works with are people with schizophrenia and people with post-traumatic stress disorder. Dr. Fischer also has a long-standing interest in research ethics.
Clinical SpecialityDr. Fischer has clinical expertise in treatment of psychotic disorders: therapy (group, family, individual) and psychopharmacology (including expertise prescribing clozapine).
Fischer IV BA. A summary of important documents in the field of research ethics. Schizophr Bull 2006; 32 (1), 69-80.
Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: Commentary. Schizophr Bull 2006; 32 (2): 246-9.
Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Med-Psych Drug-Drug Interactions Update: Clozapine Case Series. Psychosomatics 2007; 48:170-5.
Fischer BA, Weiner E. Clozapine levels lowered by modafinil: A case report and brief review of modafinil in schizophrenia. Clinical Schizophrenia & Related Psychoses 2008; 2(1): 88-90.
Fischer BA, Carpenter Jr WT. Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology 2009; 34(9):2081-7.
Faculty members: Update your contact information and create a profile.